ProQR Therapeutics (PRQR) Current Deferred Revenue (2014 - 2026)

ProQR Therapeutics (PRQR) has reported Current Deferred Revenue for 11 consecutive years, with $22.3 million the latest figure, recorded in Q1 2026.

• Quarterly Current Deferred Revenue rose 1.85% year-over-year to $22.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.3 million (up 1.85% YoY) and the FY2025 annual result came in at $20.0 million, down 20.01% from the prior year.
• Current Deferred Revenue improved to $22.3 million in Q1 2026 per PRQR's latest filing, from $20.0 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for PRQR reached as high as $28.3 million in Q3 2024 and fell as low as $6.4 million in Q4 2022.
• A 5-year average of $17.7 million and a median of $19.9 million in 2025 frame the typical range for Current Deferred Revenue.
• The largest YoY upside for Current Deferred Revenue was 311.33% in 2022 against a maximum downside of 56.85% in 2022.
• Year by year, Current Deferred Revenue stood at $6.4 million in 2022, then surged by 264.63% to $23.4 million in 2023, then grew by 6.68% to $25.0 million in 2024, then fell by 20.01% to $20.0 million in 2025, then gained by 11.71% to $22.3 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $22.3 million, $20.0 million, and $19.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.